Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction. It is being investigated for cancers.
Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction. It is being investigated for cancers.
No indication information available.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.